The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder
Abstract
Background The potential advantages of osmotic-release oral system (OROS) methylphenidate (Concerta) over immediate-release (IR) methylphenidate (Rubifen) in adults with attention-deficit hyperactivity disorder (ADHD), with respect to medication adherence, effectiveness and tolerability, are yet to be determined.Objective To compare the adherence, effectiveness and tolerability of OROS methylphenidate versus IR methylphenidate in adults with ADHD. It was hypothesized (after data collection) that adherence and effectiveness would be higher with OROS methylphenidate than with the IR formulation.Study design A chart review was carried out from April 2004 until April 2005.Setting Adult ADHD outpatient program in a general hospital in Spain.Patients Seventy adults with ADHD who met DSM-IV-TR criteria and who did not have any other current major psychiatric disorder.Intervention Patients were treated with IR methylphenidate three times daily for 3 months and then switched to OROS methylphenidate once daily.Main outcome measure Effectiveness was assessed by means of the ADHD rating scale-IV (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale at 3 months (coinciding with treatment switch) and at 6 months. The Simplified Medication Adherence Questionnaire (SMAQ) was used to assess treatment adherence, and was administered at both 3 and 6 months.Results Seventy adult ADHD patients (mean age +/- SD: 30 +/- 9.6 years; n = 48 men [68.6%]) were included in this study. The mean baseline ADHD-RS-IV score was 34.6 (SD = 10.9). The mean daily dose of IR methylphenidate was 52.1 mg (SD = 13.8 mg) administered as three divided doses. After the treatment switch, the mean OROS methylphenidate daily dose was 57.9 mg (SD = 16.5 mg) administered once daily. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0.0005) in reducing symptoms of ADHD. The percentage of responders was 28.6% with IR methylphenidate and 91.4% with the OROS formulation (p = 0.0005). OROS methylphenidate was preferred by 97% of patients. The most common adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate). No patients stopped treatment with methylphenidate because of adverse events.Conclusions The switch from IR to OROS methylphenidate was associated with an improvement in both adherence and effectiveness. There were no differences between IR and OROS methylphenidate in terms of tolerability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compliance to such frequent dosing regimens is however poor in ADHD patients due to forgetfulness, inattentiveness and self-organisation problems, leading to daily instability by frequent rebound symptoms and ineffective treatment [148,289-291].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [291]
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
(1997) · American Psychiatric Press eBooks · Cited by 3,056
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
(1998) · Cited by 2,026
Attention-deficit hyperactivity disorder
Biederman, J., & Faraone, S. V. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66915-2 · Cited by 1,463
Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder
Fayyad, J., De Graaf, R., Kessler, R., Alonso, J., Angermeyer, M., Demyttenaere, K., De Girolamo, G., Haro, J. M., Karam, E. G., Lara, C., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.034389 · Cited by 1,321
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
What Is the Prevalence of Adult ADHD? Results of a Population Screen of 966 Adults
Faraone, S. V., & Biederman, J. (2005) · Journal of Attention Disorders · doi:10.1177/1087054705281478 · Cited by 503
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Research works printed but not linked: 3
- Biederman, 2006, MedGenMed, 8, 12
- Schachter, 2001, CMAJ, 165, 1475
- Steele, 2006, Can J Clin Pharmacol, 13, e50
Cited by
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Compliance to such frequent dosing regimens is however poor in ADHD patients due to forgetfulness, inattentiveness and self-organisation problems, leading to daily instability by frequent rebound symptoms and ineffective treatment [148,289-291].”
Self-citationSkirrow, C., McLoughlin, G., Kuntsi, J., & Asherson, P. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.2 · Cited by 217
Sikirica, V., Lu, M., Greven, P., Zhong, Y., Qin, P., Xie, J., & Gajria, K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s65721 · Cited by 206
“Of the ten survey studies, three compared adherence between LA and SA stimulants.(43,49,55) Among these three studies, LA stimulants were found to have better adherence (ranging between 74.”
BackgroundCastells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11539440-000000000-00000 · Cited by 197
Self-citationAttention deficit hyperactivity disorder in adults
Rösler, M., Casas, M., Konofal, É., & Buitelaar, J. K. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.483249 · Cited by 170
“Similarly, results from a chart review of Spanish adults with ADHD reported that switching from MPH-IR to OROS MPH was associated with an improvement in compliance, as rated by the Simplifi ed Medication Adherence Questionnaire (Ramos-Quiroga et al. 2008).”
Self-citation
Metadata
- Authors
- Ramos-Quiroga, J. A., Bosch, R., Castells, X., Valero, S., Nogueira, M., Gómez, N., Yelmo, S., Ferrer, M., Martínez, Y., & Casas, M.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Universitat Autònoma de Barcelona (ES)
- Venue
- CNS Drugs
- Published
- 2008
- Volume
- 22
- Issue
- 7
- Pages
- 603-611
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2197133068
- Cited by
- 54
- References
- 31
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 5
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- OROS methylphenidate, immediate-release methylphenidate, sustained-release formulation, osmotic-release oral system, adult ADHD, medication adherence, treatment effectiveness, tolerability, treatment switching, ADHD Rating Scale-IV, CGI-I, Simplified Medication Adherence Questionnaire, stimulant medication, ADHD medication
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Chemistry, Pharmaceutical, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Methylphenidate, Outpatients, Retrospective Studies, Spain, Time Factors, Infusion Pumps, Implantable, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder. https://app.cochat.ai/papers/10.2165/00023210-200822070-00005
- The paper
- Ramos-Quiroga, J. A., Bosch, R., Castells, X., Valero, S., Nogueira, M., Gómez, N., Yelmo, S., Ferrer, M., Martínez, Y., & Casas, M. (2008). Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs. https://doi.org/10.2165/00023210-200822070-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.